Markets:

Overview

News

Currencies

International

Treasuries

Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

13.40 -0.20 (-1.47%)

Streaming Delayed Price Updated: 2:31 PM EDT, Sep 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Churchill Capital Corp XI - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

May 06, 2022

It's the final day of trading this week and it begins with a deep dive into the biggest pre-market stock movers for Friday!

Via InvestorPlace

24 Stocks Moving in Friday's Pre-Market Session ↗

May 06, 2022

Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 35% to $3.47 in pre-market trading. Vinco Ventures set record date as May 18, 2022 For dividend of shares related to Cryptyde deal. The dividend...

Via Benzinga

ChemoCentryx: Q1 Earnings Insights ↗

May 05, 2022

ChemoCentryx (NASDAQ:CCXI) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ChemoCentryx missed estimated...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 05, 2022

Gainers

Via Benzinga

ChemoCentryx Posts Favorable PK, PD Results Of Oral PD-L1 Inhibitor In Cancer ↗

April 13, 2022

Via Benzinga

Why ChemoCentryx Shares Are Falling ↗

March 02, 2022

ChemoCentryx Inc (NASDAQ:CCXI) shares are trading lower by...

Via Benzinga

ChemoCentryx's Earnings: A Preview ↗

May 04, 2022

ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx...

Via Benzinga

NASDAQ: CCXI Investor Notice: Update in Lawsuit Against ChemoCentryx, Inc. Announced ↗

April 26, 2022

San Diego, CA -- (SBWIRE) -- 04/26/2022 -- An update was announced in the lawsuit that is pending for certain investors in in shares of ChemoCentryx, Inc. (NASDAQ: CCXI) against ChemoCentryx, Inc.over...

Via SBWire

Bonds Are Screaming “Recession.” That’s Great News For One Top Sector. ↗

March 29, 2022

The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession.

Via InvestorPlace

CHEMOCENTRYX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ChemoCentryx, Inc. - CCXI

March 18, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

March 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Recap: ChemoCentryx Q4 Earnings ↗

March 01, 2022

ChemoCentryx (NASDAQ:CCXI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

ChemoCentryx's Return On Capital Employed Insights ↗

March 04, 2022

ChemoCentryx (NASDAQ:CCXI) brought in sales totaling $2.31 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 81.68%, resulting in a loss of...

Via Benzinga

68 Biggest Movers From Yesterday ↗

March 03, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to...

Via Benzinga

Earnings Preview: ChemoCentryx ↗

February 28, 2022

ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Why ChemoCentryx Shares Are Rising ↗

January 19, 2022

ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher a...

Via Benzinga

See Why Is Stifel Analyst 'Perplexed' After ChemoCentryx Q4 Earnings ↗

March 02, 2022

Stifel has reiterated a Buy rating and $85 price target on ChemoCentryx Inc (NASDAQ: CCXI) following the Q4 results. Analyst Dae Gon Ha says he is "...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 02, 2022

Gainers Trevi Therapeutics (NASDAQ:TRVI) shares rose 46.6% to $1.28 during Wednesday's regular session. As of 12:30 EST, Trevi Therapeutics's stock is trading at a...

Via Benzinga

41 Stocks Moving In Wednesday's Mid-Day Session ↗

March 02, 2022

Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 02, 2022

Gainers IsoPlexis (NASDAQ:ISO) shares moved upwards by 22.8% to $5.5 during Wednesday's pre-market session. The company's market cap stands at $214.2 million. The...

Via Benzinga

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi ↗

March 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

March 02, 2022

Rise and shine, trader! It's time to start off another day of trading with the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

28 Stocks Moving in Wednesday's Pre-Market Session ↗

March 02, 2022

Gainers Guardion Health Sciences, Inc. (NASDAQ: GHSI) rose 46.4% to $0.4098 in pre-market trading after jumping around 48% on Tuesday. Guardion Health Sciences recently reported...

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Is Now The Time To Buy Stock In ChemoCentryx, Ideanomics Or Snowflake? ↗

February 25, 2022

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings b...

Via Benzinga

NASDAQ:CCXI Long Term Investor Alert: Investigation of Potential Wrongdoing at ChemoCentryx, Inc. ↗

February 24, 2022

San Diego, CA -- (SBWIRE) -- 02/24/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of ChemoCentryx, Inc.

Via SBWire

NASDAQ:CCXI Investor Notice: Investigation over Possible Securities Laws Violations by ChemoCentryx, Inc. ↗

February 22, 2022

San Diego, CA -- (SBWIRE) -- 02/22/2022 -- ChemoCentryx, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

SHAREHOLDER ALERT: Robbins LLP Investigates ChemoCentryx, Inc. (CCXI) on Behalf of Shareholders

January 27, 2022

From Robbins LLP

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Penticton Herald

Penticton Herald

Churchill Capital Corp XI - Class A Ordinary Shares (NQ:CCXI)

All News about Churchill Capital Corp XI - Class A Ordinary Shares

Contact us

Sections

Services

Search